It's really funny to think about how things have progressed so far considering the relatively short time the company has been active. So.. I might be off base, but I get the feeling that it goes something like this:
-New company forms around the larkish idea to license the use of a novel "human brain simulator" developed by the largest public research institution in Canada; a big focus was planned to have been on novel psychedelic interactions. I'm guessing it's based on the newly-developed neuromorphic chip architecture, and it sounds a lot like they've got it hooked up with synthetic neurons in order to more accurately reproduce in silico results. -Shortly after spinning it up, it provides all the data that lays the foundation for the company's research pipeline. A few candidates clearly stand out. -To secure funding, it is decided to sell the psilocybin IP to another company, Revive Therapeutics; they're also exploring the drug repurposing field, so it dovetails nicely. Equities are exchanged. -It feels like around January or February that some new information came to light regarding the potential efficacy of ketamine with Parkinson's disease, because the company appears to have started focusing more attention in that direction. The name is changed from Newscope Capital Corp to PharmaTher in order to more-accurately reflect that shift. -We are here, and now we're waiting on Phase II trials to commence.
I mean... I see a swift pivot to a huge unaddressed market, and I see that it's foundation is based on empirical data stemming back at least five years. Go ahead and do a quick Google search for "ketamine Parkinson's," and you might get a better idea of the potential here. It looks to me as if the medical research community is starting to come around on these orphan drugs...
Oh and the other thing that nobody wants to think about: viral-mediated anosmia is scary to those that are aware of the potential implications: Parkinson's disease is one of the few diseases preceded by anosmia, so it's not great that it's the same case with covid-19. There aren't many people throwing this thought around, but I'm starting to think that we might see more cases of Parkinson's pop up in the future... It isn't a great thesis to bank on, but it might also explain some things...
G
So why is this not trading today with PR out??? 🧐
C
needs volume. otherwise we are sitting still
C
I just bought 10000 today, this is a gem! only thing very low volume
A
I like psychedelic play because they are using Ketamine . Which has FDA approval for depression similar to Johnson & Johnson’s intravenous breakthrough medication. These guys just have a much better delivery system. This will be quick to market, proven product and safe.
A
Huge News! This is the perfect guy to bring on board. Dr. Fava is Psychiatrist-in-Chief of the Massachusetts General Hospital (“MGH”), director, Division of Clinical Research of the MGH Research Institute, executive director of the Clinical Trials Network and Institute, (MGH), associate dean for clinical and translational research and the Slater Family Professor of Psychiatry at Harvard Medical School.
A
Here we go. One big catalyst for the sector and this instantly doubles
B
Anyone still out there on this page
C
pretty boring 37k lol wowwwwww. I'm tired after a boring day
A
Was there insider news today?
M
Entered by .42 )))) Voted "for", where is my Moon? )))
F
I'm going to start doubling down, looks like it has bottomed
r
Time to buy thus one
F
BUYING MORE UNDER .40
C
This one has nowhere to go but up over the next year.
r
Time to load
H
wow absolutely great news! $1 in the near future
N
Does anyone know what is coming down the pipeline from PHRM? There’s a little insight on interviews on YouTube but not much details were provided? Thanks.
T
considering adding more of this, just not sure
M
Bought in today for 10k shares. long & strong!!! GLTA!!!
-New company forms around the larkish idea to license the use of a novel "human brain simulator" developed by the largest public research institution in Canada; a big focus was planned to have been on novel psychedelic interactions. I'm guessing it's based on the newly-developed neuromorphic chip architecture, and it sounds a lot like they've got it hooked up with synthetic neurons in order to more accurately reproduce in silico results.
-Shortly after spinning it up, it provides all the data that lays the foundation for the company's research pipeline. A few candidates clearly stand out.
-To secure funding, it is decided to sell the psilocybin IP to another company, Revive Therapeutics; they're also exploring the drug repurposing field, so it dovetails nicely. Equities are exchanged.
-It feels like around January or February that some new information came to light regarding the potential efficacy of ketamine with Parkinson's disease, because the company appears to have started focusing more attention in that direction. The name is changed from Newscope Capital Corp to PharmaTher in order to more-accurately reflect that shift.
-We are here, and now we're waiting on Phase II trials to commence.
I mean... I see a swift pivot to a huge unaddressed market, and I see that it's foundation is based on empirical data stemming back at least five years. Go ahead and do a quick Google search for "ketamine Parkinson's," and you might get a better idea of the potential here. It looks to me as if the medical research community is starting to come around on these orphan drugs...
Oh and the other thing that nobody wants to think about: viral-mediated anosmia is scary to those that are aware of the potential implications: Parkinson's disease is one of the few diseases preceded by anosmia, so it's not great that it's the same case with covid-19. There aren't many people throwing this thought around, but I'm starting to think that we might see more cases of Parkinson's pop up in the future... It isn't a great thesis to bank on, but it might also explain some things...